Pfizer Inc PFE

$29.23 -0.16 (-0.54%)

Valuation

Market cap
167,518,704,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.80
P/E (forward)
9.87
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
45,546,747
Avg volume
33,616,914
Day's range
$28.98 – $29.63
Shares out
5,699,854,000
Stochastic %K
29%
Beta
0.31
Analysts
Hold
Price target
$30.35

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Chelsea100 Nov 9, 6:06 PM
$NVAX My biggest hope is $PFE. Sanofi has already made its move and advanced CiC into Phase 3. Moderna still faces hurdles in the US CiC market. $NVAX has its own CiC candidate with Phase 2 data. Pfizer, AstraZeneca, or another Big Pharma player could step in and strike the DEAL OF ALL DEALS! And here's the difference: Novavax is no longer negotiating from a position of desperation. They have cash, partnerships, and time. For fuck's sake, I refuse to give up on the possibility that we're closer than ever to a massive breakthrough. ONE HUGE DEAL could send $NVAX flying and ignite the mother of all SHORT SQUEEZES! 47 MILLION shares short. Imagine the scramble to cover!
1 replies
smartfellar Nov 9, 5:47 PM
$PFE almost de-pegged there for a minute, but we are back to stablecoin status
0 replies
PFElinepfrenzy1990 Nov 9, 5:15 PM 1 replies
DocPharm Nov 9, 5:00 PM
$ROIV at least a couple of the gems keep moving $PFE 💪💪💪 $ABUS lagging for no reason; as always
0 replies
taxplanr Nov 9, 4:22 PM 0 replies
MrPeanutEsquire Nov 9, 3:51 PM
$PFE Lilly looks like they are having fun out there...
1 replies
Stocktradesmoon Nov 9, 3:36 PM
$ABCL $HIMS $REGN $PFE $SLS 🚨 $ABCL Hiring Update AbCellera’s careers board just increased from 36 to 37 openings, with a newly listed Senior CMC Regulatory Affairs Manager position in Montreal. This is a distinct requisition from the existing Vancouver role. CMC regulatory expertise is critical for regulatory submissions, manufacturing readiness, and late-stage clinical development. With ABCL635 progressing toward Phase 3, the continued expansion of AbCellera’s regulatory and development infrastructure is encouraging. Not confirmation of a regulatory milestone, but another interesting piece of the puzzle. 👀
0 replies
Parlandoconme Nov 9, 3:36 PM
$TOMZ 7 figure bio pharma deals in the pipe. If $AZN and $PFE are spraying the mist it must be good. Any BSL-4 labs trying steramist? buy baby buy
0 replies